ABB: Q4 2022 Results
ABB (SWX:ABBN):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005955/en/
|
KEY FIGURES |
|
|
|
|
|
|
|
|
||||
|
|
|
|
CHANGE |
|
|
CHANGE |
||||||
|
($ millions, unless otherwise indicated) |
Q4 2022 |
Q4 2021 |
US$ |
Comparable1 |
FY 2022 |
FY 2021 |
US$ |
Comparable1 |
||||
|
Orders |
7,620 |
8,257 |
-8% |
2% |
33,988 |
31,868 |
7% |
16% |
||||
|
Revenues |
7,824 |
7,567 |
3% |
16% |
29,446 |
28,945 |
2% |
12% |
||||
|
Gross Profit |
2,658 |
2,397 |
11% |
|
9,710 |
9,467 |
3% |
|
||||
|
as % of revenues |
34.0% |
31.7% |
+2.3 pts |
|
33.0% |
32.7% |
+0.3 pts |
|
||||
|
Income from operations |
1,185 |
2,975 |
-60% |
|
3,337 |
5,718 |
-42% |
|
||||
|
Operational EBITA1 |
1,146 |
988 |
16% |
28% 3 |
4,510 |
4,122 |
9% |
18% 3 |
||||
|
as % of operational revenues1 |
14.8% |
13.1% |
+1.7 pts |
|
15.3% |
14.2% |
+1.1 pts |
|
||||
|
Income from continuing operations, net of tax |
1,168 |
2,703 |
-57% |
|
2,637 |
4,730 |
-44% |
|
||||
|
Net income attributable to ABB |
1,132 |
2,640 |
-57% |
|
2,475 |
4,546 |
-46% |
|
||||
|
Basic earnings per share ($) |
0.61 |
1.34 |
-55%2 |
|
1.30 |
2.27 |
-43%2 |
|
||||
|
Cash flow from operating activities4 |
687 |
1,020 |
-33% |
|
1,287 |
3,330 |
-61% |
|
||||
|
Cash flow from operating activities in continuing operations |
720 |
1,033 |
-30% |
|
1,334 |
3,338 |
-60% |
|
||||
|
1 For a reconciliation of non-GAAP measures, see “supplemental reconciliations and definitions” in the attached Q4 2022 Financial Information. |
||||||||||||
|
2 EPS growth rates are computed using unrounded amounts. 2021 numbers include the impact related to the divestment of Mechanical Power Transmission. |
||||||||||||
|
3 Constant currency (not adjusted for portfolio changes). |
||||||||||||
|
4 Amount represents total for both continuing and discontinued operations. |
||||||||||||
“2022 was another successful year for ABB, including a further streamlining of our business portfolio and achieving our margin target earlier than expected. We have made ABB more resilient. In 2023, regardless of current market uncertainty, we want to show that we can continuously deliver an Operational EBITA margin of at least 15%.”
Björn Rosengren, CEO
CEO summary
In the fourth quarter of 2022, we improved comparable orders and revenues, we increased our Operational EBITA by 16%, raised our Operational EBITA margin by 170 basis points and lifted ROCE to 16.5% for 2022, to within our target range. All in all, this was a good achievement in my view.
Customer activity improved slightly or remained stable in most customer segments, except for declines related to residential construction and discrete manufacturing. The market outlook for discrete manufacturing remains solid, although the fourth quarter was adversely impacted by customers normalizing order patterns following a period of pre-ordering triggered by the long delivery lead times in a strained value chain. This weighed on order intake in Robotics & Discrete Automation, while the other three business areas remained stable or increased comparable orders. Revenues were strong and increased by 3% (16% comparable). The Americas region was the growth engine for orders, while Europe reversed and Asia, Middle East and Africa remained overall largely stable despite a decline in China. The escalating Covid-related situation in China somewhat slowed down local business activity towards the end of the period. Our priority is to keep our people safe.
Our strong price execution combined with increased volumes supported the higher gross margin and drove the improvement of 170 basis points in the Operational EBITA margin to 14.8%, the strongest fourth quarter margin in several years. This resulted in 2022 being a record year for ABB, in recent history, with an Operational EBITA margin of 15.3%. We achieved good price management, executed well on increased volumes with some additional support from unusually low corporate costs. I am pleased how the divisions managed challenges like supply chain constraints, a tight labor market, Covid-related lock downs in China and a high inflationary environment.
Cash flow of $687 million in the quarter is the one area which did not quite meet our expectations as the depletion of net working capital was slower than anticipated. This will be an important focus area for us near term as we deliver against our high order backlog. As earlier announced, the finalization of the Kusile-related issues weighed on cash flow by approximately $315 million, while the closing of the divestment of Power Grids generated a net cash contribution in investing activities of $1.4 billion.
We remain committed to our plans to separately list our E-mobility business, subject to constructive market conditions. Meanwhile, we have closed by the end of January the pre-IPO private placement of approximately CHF525 million for newly issued shares to new minority investors representing approximately 20% ownership of the E-mobility business. The proceeds will be used to capture E-mobility’s growth potential through organic and M&A investments in hardware and software.
Just after the close of the fourth quarter, we progressed with the final part of our announced divisional exits by signing an agreement to divest the Power Conversion division in the Electrification business area. From here on, we will continue to review our business portfolio on a product group level within our current divisions. One example is our decision to initiate the exit of the emergency lighting business within the Smart Buildings division in the Electrification business area during 2023.
By partnering with the Swedish mining and smelting company Boliden to build a strategic co-operation to use low carbon footprint copper in our electromagnetic stirring (EMS) equipment and high-efficiency electric motors, we took another step towards our 2030 target of having a circular approach in at least 80 percent of our products and solutions. The aim is to reduce greenhouse gas (GHG) emissions while driving the transition to a more circular economy.
Looking into 2023, we currently do not anticipate a major set-back in demand, although the high inflationary environment adds uncertainty. Comparable order growth, at least in the first half of the year, should be somewhat hampered by last year’s very high order level coupled with a normalization of customers’ order pattern after a period of pre-ordering in times of a strained value chain. I expect comparable revenue growth to be above 5%, supported by backlog execution. Cash flow should benefit from us working down the net working capital, and we should also have less adverse items impacting comparability. I view 2023 as a good opportunity for ABB to prove that we can continuously deliver an annual Operational EBITA margin of at least 15%.
Considering improving performance, robust cash flow and a solid balance sheet, the Board of Directors proposes an ordinary dividend of CHF0.84 per share. Up from CHF0.82 in the previous year and in line with the long-term ambition of a rising sustainable dividend per share over time, while still prioritizing a solid balance sheet to support our growth ambitions. We plan to continue with share buybacks for full year of 2023.
Björn Rosengren
CEO
Outlook
In the first quarter of 2023, we anticipate double-digit comparable revenue growth to support some improvement in the Operational EBITA margin, year-on-year.
In full-year 2023, despite current market uncertainty, we anticipate comparable revenue growth to be above 5% and we expect to again achieve our long-term target of Operational EBITA margin of at least 15%.
The complete press release including the appendices is available at www.abb.com/news.
ABB (ABBN: SIX Swiss Ex) is a technology leader in electrification and automation, enabling a more sustainable and resource-efficient future. The company’s solutions connect engineering know-how and software to optimize how things are manufactured, moved, powered and operated. Building on more than 130 years of excellence, ABB’s ~105,000 employees are committed to driving innovations that accelerate industrial transformation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005955/en/
Contact information
ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland
Media Relations
+41 43 317 71 11
media.relations@ch.abb.com
Investor Relations
+41 43 317 71 11
investor.relations@ch.abb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business1.12.2025 09:00:00 EET | Press release
Regnology, a global leader in regulatory reporting and supervisory technology, today announces the successful closing of its acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) business. This milestone reinforces Regnology’s position as the trusted partner for financial institutions and regulators worldwide, delivering smarter, faster compliance solutions at scale. Regnology is committed to ensuring business continuity for all FRR clients. With a proven track record in seamless migrations and a unified data model on a scalable SaaS platform, institutions can maintain compliance securely and efficiently throughout the integration process. The acquisition underscores Regnology’s vision to combine regulatory expertise with innovation. The recently launched RRH Ascend platform exemplifies this commitment, offering cloud-native architecture, advanced automation, and AI-driven insights to transform regulatory data into strategic value. By integrating Wolters Kluwer’s F
Ant International Upgrades Antom Copilot to Advance Domain-Specific Agentic AI to Solve Global Payment Complexity1.12.2025 08:21:00 EET | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced major upgrades to Antom Copilot, its industry-first AI agent designed for merchant payment and operations management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251130027598/en/ Antom Copilot supports a wide range of merchant payment operations and responds to early signs of issues with tailored recommendations. Integrated into the Antom Merchant Portal, Antom Copilot now provides enhanced automation and tailored assistance based on learnings from real-world cases, to help merchants handle payment complexity more efficiently. Main features include: Agentic support for entire payment lifecycle, from onboarding and integration, to dispute handling, risk control and payment success rate operation; Domain-trained intelligence functions like a virtual team of payment experts to manage traditionally resource-intensive
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe1.12.2025 08:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability challenges. And bone-related events resulting from bone metastases significantly impact a patient's quality of life, leading to death if not treated fast enough. Our biosimilars aim to improve access, enable timely care, and ease the financial burden on healthcare systems.”, said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial Division at Samsung Bioepis. “With our proven track records, we’re confident that OBODENCE and XBRYK will deliver meaningful impact on patients and their communities.” OBODENCE, refer
UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs28.11.2025 23:31:00 EET | Press release
The UAE’s Artificial Intelligence, Digital Economy, and Remote Work Applications Office announced that Google Gemini has ranked first in the “AI in the Ring” Index, the world’s first benchmark designed to evaluate how effectively AI language models reflect Emirati culture, dialects, traditions, and national values through a challenge centered on cultural intelligence within the UAE context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128785463/en/ UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs (Photo: AETOSWire) Gemini earned the top ranking following a review of over 400 questions across 7 cultural dimensions and 5,200 generated responses from 11 major language models. A Committee of Emirati experts evaluated the outputs to identify which models demonstrated the strongest cultural understanding. Following Gemini 2.5 Pro, the list of the top five high-performing models included: ChatGPT (O
GE HealthCare announces CE Mark for the Omni 128cm total body PET/CT system28.11.2025 13:00:00 EET | Press release
GE HealthCare today announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system,i a major milestone in its mission to advance precision care. Designed to advance cancer diagnosis, staging, therapeutic planning and treatment response monitoring, this innovative system represents a leap forward in molecular imaging capabilities and clinical efficiency. As global cancer rates continue to rise – projected to increase 77 percent by 2050ii – the need for advanced imaging solutions has never been greater. The growing prevalence of cancer and emergence of investigational immunotherapies and targeted treatments have accelerated the demand for whole-body PET/CT imaging. GE HealthCare’s new technology is built to meet this need, supporting theranostics and enabling clinicians to visualize, diagnose and monitor disease with impressive precision and speed. “Our commitment to precision health is rooted in innovation that also aim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
